Together with TCGA data showing that FADD amplification and overexpression implicated in sensitivity to the combination is not commonly observed in HPV(+) HNSCC, these observations raised the question whether the SMAC mimetic birinapant could be used in combination with TRAIL or TRAIL agonists for treating this type of cancer. This evidence concerns the gene FADD and cancer.